CommercialPrior AuthMedium impact
State and School Employees' Health Insurance Plan - Adakveo (crizanlizumab-tmca)
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology·Medical Policy
We identified it
Jun 20, 2026
Summary
New policy establishes coverage criteria for Adakveo (crizanlizumab-tmca) for sickle cell disease patients 16+ years old. Prior authorization required with specific criteria including documented pain crises, hydroxyurea trial/intolerance, and specialist involvement.
Action Required
Immediately: Update prior authorization workflows for HCPCS code J0791 (crizanlizumab-tmca injection). Billing team must verify patients meet ALL criteria: age 16+, documented sickle cell disease, 2+ pain crises in past 12 months, hydroxyurea trial or contraindication, pregnancy status confirmation for females, and specialist involvement. Create checklist for authorization requests as claims will be denied without proper documentation.